vs
Side-by-side financial comparison of Freeport-McMoRan (FCX) and Medline Inc. (MDLN). Click either name above to swap in a different company.
Medline Inc. is the larger business by last-quarter revenue ($7.4B vs $5.3B, roughly 1.4× Freeport-McMoRan). Freeport-McMoRan runs the higher net margin — 10.7% vs 3.3%, a 7.5% gap on every dollar of revenue. On growth, Medline Inc. posted the faster year-over-year revenue change (10.7% vs -10.4%). Medline Inc. produced more free cash flow last quarter ($316.0M vs $-312.0M).
Freeport-McMoRan Inc., often called Freeport, is an American mining company based in the Freeport-McMoRan Center, in Phoenix, Arizona. The company is the world's largest producer of molybdenum, a major copper producer and operates the world's largest gold mine, the Grasberg mine in Papua, Indonesia.
Medline Inc. is an American public healthcare company headquartered in Northfield, Illinois. In June 2021 it was acquired by a consortium of private equity firms Blackstone, Carlyle and Hellman & Friedman valuing the company at $34 billion in one of the largest leveraged buyouts of all time. It was the nation's largest privately held manufacturer and distributor of medical supplies providing products, education, clinical programs and services across the continuum of care with operations in ov...
FCX vs MDLN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $5.3B | $7.4B |
| Net Profit | $565.0M | $239.0M |
| Gross Margin | 12.4% | 25.0% |
| Operating Margin | 15.4% | 5.7% |
| Net Margin | 10.7% | 3.3% |
| Revenue YoY | -10.4% | 10.7% |
| Net Profit YoY | -21.6% | -59.9% |
| EPS (diluted) | — | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $7.4B | ||
| Q4 25 | $5.3B | — | ||
| Q3 25 | $6.8B | — | ||
| Q2 25 | $7.5B | — | ||
| Q1 25 | $5.6B | — | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $6.4B | — |
| Q1 26 | — | $239.0M | ||
| Q4 25 | $565.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $793.0M | — | ||
| Q4 24 | $721.0M | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.3B | — |
| Q1 26 | — | 25.0% | ||
| Q4 25 | 12.4% | — | ||
| Q3 25 | 29.2% | — | ||
| Q2 25 | 34.2% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 27.0% | — | ||
| Q3 24 | 30.0% | — | ||
| Q2 24 | 31.5% | — |
| Q1 26 | — | 5.7% | ||
| Q4 25 | 15.4% | — | ||
| Q3 25 | 28.9% | — | ||
| Q2 25 | 32.3% | — | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 21.1% | — | ||
| Q3 24 | 29.0% | — | ||
| Q2 24 | 32.0% | — |
| Q1 26 | — | 3.3% | ||
| Q4 25 | 10.7% | — | ||
| Q3 25 | 18.3% | — | ||
| Q2 25 | 20.6% | — | ||
| Q1 25 | 14.2% | — | ||
| Q4 24 | 12.3% | — | ||
| Q3 24 | 18.5% | — | ||
| Q2 24 | 20.0% | — |
| Q1 26 | — | $0.16 | ||
| Q4 25 | — | — | ||
| Q3 25 | $0.46 | — | ||
| Q2 25 | $0.53 | — | ||
| Q1 25 | $0.24 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0.36 | — | ||
| Q2 24 | $0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.8B | $2.2B |
| Total DebtLower is stronger | $9.4B | $12.5B |
| Stockholders' EquityBook value | $18.9B | $19.3B |
| Total Assets | $58.2B | $39.0B |
| Debt / EquityLower = less leverage | 0.50× | 0.65× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.2B | ||
| Q4 25 | $3.8B | — | ||
| Q3 25 | $4.3B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $3.9B | — | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $5.3B | — |
| Q1 26 | — | $12.5B | ||
| Q4 25 | $9.4B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $9.4B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $9.7B | — | ||
| Q2 24 | $9.4B | — |
| Q1 26 | — | $19.3B | ||
| Q4 25 | $18.9B | — | ||
| Q3 25 | $18.7B | — | ||
| Q2 25 | $18.2B | — | ||
| Q1 25 | $17.7B | — | ||
| Q4 24 | $17.6B | — | ||
| Q3 24 | $17.5B | — | ||
| Q2 24 | $17.4B | — |
| Q1 26 | — | $39.0B | ||
| Q4 25 | $58.2B | — | ||
| Q3 25 | $56.8B | — | ||
| Q2 25 | $56.5B | — | ||
| Q1 25 | $56.0B | — | ||
| Q4 24 | $54.8B | — | ||
| Q3 24 | $55.4B | — | ||
| Q2 24 | $54.6B | — |
| Q1 26 | — | 0.65× | ||
| Q4 25 | 0.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.53× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.55× | — | ||
| Q2 24 | 0.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $693.0M | $412.0M |
| Free Cash FlowOCF − Capex | $-312.0M | $316.0M |
| FCF MarginFCF / Revenue | -5.9% | 4.3% |
| Capex IntensityCapex / Revenue | 19.1% | 1.3% |
| Cash ConversionOCF / Net Profit | 1.23× | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $1.1B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $412.0M | ||
| Q4 25 | $693.0M | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.9B | — | ||
| Q2 24 | $2.0B | — |
| Q1 26 | — | $316.0M | ||
| Q4 25 | $-312.0M | — | ||
| Q3 25 | $608.0M | — | ||
| Q2 25 | $934.0M | — | ||
| Q1 25 | $-114.0M | — | ||
| Q4 24 | $197.0M | — | ||
| Q3 24 | $673.0M | — | ||
| Q2 24 | $840.0M | — |
| Q1 26 | — | 4.3% | ||
| Q4 25 | -5.9% | — | ||
| Q3 25 | 8.9% | — | ||
| Q2 25 | 12.4% | — | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 10.1% | — | ||
| Q2 24 | 13.1% | — |
| Q1 26 | — | 1.3% | ||
| Q4 25 | 19.1% | — | ||
| Q3 25 | 15.5% | — | ||
| Q2 25 | 16.8% | — | ||
| Q1 25 | 21.0% | — | ||
| Q4 24 | 21.1% | — | ||
| Q3 24 | 17.9% | — | ||
| Q2 24 | 17.4% | — |
| Q1 26 | — | 1.72× | ||
| Q4 25 | 1.23× | — | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 1.42× | — | ||
| Q1 25 | 1.33× | — | ||
| Q4 24 | 1.99× | — | ||
| Q3 24 | 1.51× | — | ||
| Q2 24 | 1.53× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FCX
| Morenci | $2.5B | 47% |
| Grasberg Segment | $964.0M | 18% |
| Copper In Concentrates | $934.0M | 18% |
| Molybdenum | $541.0M | 10% |
| Gold | $388.0M | 7% |
MDLN
| Supply Chain Solutions segment | $3.9B | 53% |
| Medline Brand segment | $3.5B | 47% |
